Chronic graft versus host disease

Researchers are testing whether infusions of bone marrow-derived mesenchymal stem cells, called MesenCell, are safe for adults with moderate or severe chronic graft-versus-host disease that has not responded to steroids and other standard treatments. The trial enrolls up to 20 pe…

This phase 3 trial is testing whether the oral drug belumosudil works better than the best available therapy for people aged 12 and older with chronic graft-versus-host disease (cGVHD) that has not improved or has returned after 2 to 5 prior treatments. Participants are randomly …

This early-phase study tests whether the drug sarilumab can safely help adults with chronic graft-versus-host disease (cGVHD) that did not improve with the standard drug belumosudil. Ten participants will receive sarilumab alone, and researchers will monitor side effects and drug…

This trial compares a liquid (oral suspension) form of the drug belumosudil with the standard tablet in healthy adult men. The goal is to see if the liquid version is absorbed by the body in the same way, which could offer a more convenient option for people with chronic graft-ve…

This study tests a lab-made antibody called anti-CD25 rhMAb for people with chronic graft-versus-host disease (cGVHD) of the liver that hasn't improved with steroids. The antibody is given alongside standard immune-suppressing drugs. The trial will include 30 adults aged 16-65 wh…

This phase 2 trial tests a combination of two oral drugs, ruxolitinib and belumosudil, for chronic graft-versus-host disease (cGvHD) that hasn't improved with steroids. cGvHD is a serious condition where donor immune cells attack the patient's body after a stem cell transplant. T…

This study tests the safety of a drug called belumosudil in 26 Indian patients aged 12 and older who have chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. Participants take the drug for up to 24 weeks, and doctors monitor for side effects an…

This study tests a drug called gecacitinib in 33 adults who have chronic graft-versus-host disease (cGVHD) after a stem cell transplant and whose condition hasn't improved with steroids. The goal is to find a safe dose and see if it helps control the disease. Participants take th…

This trial tests whether a mindfulness-based stress reduction program — including group sessions and one-on-one coaching — can help people living with chronic graft-versus-host disease (cGVHD) manage symptoms like pain, anxiety, and poor sleep. cGVHD is a complication that can oc…

This study looks at why some people develop chronic graft-versus-host disease (GVHD) after a stem cell transplant. Researchers will collect blood, stool, saliva, and tissue samples from 75 participants to track immune cell changes over time. The goal is to better understand the d…

This study investigates how axatilimab, an FDA-approved drug for chronic graft-versus-host disease (cGVHD), changes immune cells in the skin. Researchers will analyze skin and blood samples from 15 adults with skin cGVHD—10 starting axatilimab and 5 not receiving it—to understand…

This study looks at blood samples from 1500 stem cell transplant patients to find markers that can predict chronic graft-versus-host disease (cGVHD), a serious complication. Researchers will use mass spectrometry to analyze proteins in the blood and combine this with patient data…